摘要
目的探讨诺和锐30与诺和灵30R对于住院初诊的2型糖尿病患者的治疗效果。方法回顾性分析2010年5月～2012年9月我院收治的60例初诊T2DM患者,根据患者当时接受的治疗方法分为诺和锐30组与诺和灵30R组,各30例,两组患者分别以诺和锐30和诺和灵30R进行治疗,在经过一段时间治疗以后对患者的疗效进行观察对比。结果两组患者相对于接受治疗前,空腹血糖(FPG)、糖化血糖蛋白(HbA1C)以及餐后2h血糖(2hPBG)均有明显的下降,但是诺和锐30组的患者在HbA1C以及2hPBG方面下降更为显著(P<0.01;P<0.05);对血糖进行控制的前提上诺和锐30剂量相对于诺和灵30R少很多(P<0.05);诺和锐30组患者出现低血糖概率相对于诺和灵30R组别患者要低(P<0.05)。结论诺和锐30以及诺和灵30R均有着降低血糖指数的效果,但与诺和灵30R相比,诺和锐30对于T2DM患者在血糖水平及低血糖反应方面有着更加突出的优越性。
Objective To explore and analyze the clinical efficacy of Novomix30 and pre-mixed30R in the treatment oftype 2 diabetes mellitus （T2DM）. Methods 60 cases with T2DM in our hospital from May 2010 to September 2012 were selected and retrospectively analyzed,the patients were divided into Novomix30 group and pre-mlxed30R group according to the treatment they received,each group had 30 cases, the two groups were treated by Novomix30 and pre- mixed30R respectively.Observed and compared the efficacy of the two groups after a period of treatment. Results compared with before the treatment, FPG,HbA1C and 2hPBG of the two groups had both decreased significantly,but HbA1C and 2hPBG in Novomix30 group decreased more significantly（P 〈 0.01;P 〈 0.05）, hypoglycemia probability in Novomix30 group was lower than that in pre-mixed30R group（P 〈 0.05）. Conclusion Novomix30 and pre- mixed30R both can reduce glycemic index,but compare with pre-mixed30R,Novomix30 in blood sugar levels and hypoglycemia reaction for type 2 diabetic patients have a more prominent superiority.
出处
《中国医药科学》
2013年第12期61-62,共2页
China Medicine And Pharmacy
